Stocks TelegraphStocks Telegraph
Stock Ideas

ESPR Financial Statements and Analysis

NASDAQ : ESPR

Esperion Therapeutics, Inc.

$1.92
0.04+2.13%
Open: 10:59 AM
69.52
BESG ScoreESG Rating

ESPR FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

ESPR Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
revenue51.632M73.834M137.735M32.25M33.969M
cost of revenue17.286M15.619M10.075M11.458M13.377M
gross profit34.346M58.215M127.66M20.792M20.592M
gross profit ratio0.6650.7880.9270.6450.606
research and development expenses10.397M11.461M13.403M17.742M14.885M
general and administrative expenses00029.817M0
selling and marketing expenses00015.60M0
selling general and administrative expenses39.975M44.175M41.988M45.417M33.24M
other expenses02.454M10.075M1.08M13.377M
operating expenses50.372M55.636M65.466M63.159M61.502M
cost and expenses67.658M71.255M65.466M74.617M61.502M
interest income000900.00K1.278M
interest expense15.082M13.723M14.024M15.057M-14.995M
depreciation and amortization26.00K10.00K41.00K6.00K26.00K
ebitda-14.416M-48.192M75.046M-42.361M-27.533M
ebitda ratio-0.2790.0350.525-1.314-0.811
operating income-16.026M2.579M72.269M-42.367M-27.533M
operating income ratio-0.310.0350.525-1.314-0.811
total other income expenses net-13.498M-64.504M-11.247M-13.977M-13.717M
income before tax-29.524M-61.925M61.022M-56.344M-41.25M
income before tax ratio-0.572-0.8390.443-1.747-1.214
income tax expense00-41.00K0-26.00K
net income-29.524M-61.925M61.022M-56.344M-41.25M
net income ratio-0.572-0.8390.443-1.747-1.214
eps-0.15-0.330.36-0.50-0.37
eps diluted-0.15-0.330.34-0.50-0.37
weighted average shs out194.931M188.794M169.259M112.403M111.869M
weighted average shs out dil194.931M188.794M189.641M112.403M111.869M
Graph

ESPR Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
cash and cash equivalents144.717M189.304M226.609M82.248M114.833M
short term investments00000
cash and short term investments144.717M189.304M226.609M82.248M114.833M
net receivables67.824M60.36M54.612M48.494M42.623M
inventory80.102M84.469M73.095M65.623M51.435M
other current assets14.912M10.975M11.29M4.70M6.287M
total current assets307.555M345.108M365.606M201.065M218.227M
property plant equipment net6.503M7.155M7.398M4.675M3.022M
goodwill00000
intangible assets56.00K56.00K56.00K056.00K
goodwill and intangible assets56.00K56.00K56.00K56.00K56.00K
long term investments00000
tax assets00000
other non current assets000-1.000
total non current assets6.559M7.211M7.454M4.731M3.078M
other assets0001.000
total assets314.114M352.319M373.06M205.796M221.305M
account payables34.864M47.669M28.433M31.718M26.214M
short term debt2.741M2.679M46.025M36.381M918.00K
tax payables00000
deferred revenue15.078M20.672M29.35M25.402M19.723M
other current liabilities113.19M104.318M60.704M62.723M90.853M
total current liabilities165.873M175.338M164.512M156.224M137.708M
long term debt266.221M266.456M502.846M501.546M263.214M
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities252.229M254.745M03.02M230.387M
total non current liabilities518.45M521.201M502.846M504.566M493.601M
other liabilities001.0000
capital lease obligations6.04M3.981M4.416M3.02M2.967M
total liabilities684.323M696.539M667.358M660.79M631.309M
preferred stock001.0000
common stock195.00K195.00K188.00K118.00K112.00K
retained earnings-1.58B-1.55B-1.488B-1.549B-1.493B
accumulated other comprehensive income loss00000
other total stockholders equity1.209B1.206B1.194B1.094B1.083B
total stockholders equity-370.209M-344.22M-294.298M-454.994M-410.004M
total equity-370.209M-344.22M-294.298M-454.994M-410.004M
total liabilities and stockholders equity314.114M352.319M373.06M205.796M221.305M
minority interest00000
total investments00000
total debt268.962M556.634M548.871M540.947M264.132M
net debt124.245M367.33M322.262M458.699M149.299M
Graph

ESPR Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
deferred income tax000-17.487M0
stock based compensation3.022M2.931M3.235M2.92M2.975M
change in working capital26.802M-4.999M-21.803M3.955M6.579M
accounts receivables-7.464M-5.748M-6.118M-5.871M-1.824M
inventory4.367M-11.374M-7.472M-14.188M-5.759M
accounts payables-12.77M19.348M-3.45M5.504M1.656M
other working capital11.988M-7.225M-4.763M18.51M12.506M
other non cash items-35.214M56.778M11.374M29.894M12.345M
net cash provided by operating activities-35.325M-7.205M53.828M-37.056M-19.325M
investments in property plant and equipment-167.00K-77.00K-73.00K00
acquisitions net00000
purchases of investments00000
sales maturities of investments00000
other investing activites00000
net cash used for investing activites-167.00K-77.00K-73.00K00
debt repayment-44.926M-39.094M-5.832M-4.598M-4.292M
common stock issued-9.071M9.071M90.672M9.069M-52.459M
common stock repurchased343.75M-343.75M000
dividends paid00000
other financing activites-298.848M-30.023M-66.00K052.439M
net cash used provided by financing activities-9.095M-30.023M90.606M4.471M-4.312M
effect of forex changes on cash00000
net change in cash-44.587M-37.305M144.361M-32.585M-23.637M
cash at end of period144.717M189.304M226.609M82.248M114.833M
cash at beginning of period189.304M226.609M82.248M114.833M138.47M
operating cashflow-35.325M-7.205M53.828M-37.056M-19.325M
capital expenditure-167.00K-77.00K-73.00K00
free cash flow-35.492M-7.282M53.755M-37.056M-19.325M
Graph

Frequently Asked Questions

How did Esperion Therapeutics, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?

A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, ESPR generated $51.63M in revenue last quarter, while its costs came in at $17.29M.

Last quarter, how much Gross Profit did Esperion Therapeutics, Inc. report?

A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Esperion Therapeutics, Inc. reported a $34.35M Gross Profit for the quarter ended Sep 30, 2024.

Have ESPR's Total Operating Expenses and Operating Income been favorable recently?

Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. ESPR incurred $50.37M worth of Operating Expenses, while it generated -$16.03M worth of Operating Income.

How much Net Income has ESPR posted recently?

The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Esperion Therapeutics, Inc., the company generated -$29.52M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.

At the end of the last quarter, how much Cash and Equivalents did Esperion Therapeutics, Inc. have?

The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Esperion Therapeutics, Inc. as of the end of the last quarter was $144.72M.

What are ESPR's Total Net Receivables for the last quarter?

Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, ESPR had Total Net Receivables of $67.82M.

In terms of Total Assets and Current Assets, where did Esperion Therapeutics, Inc. stand at?

An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of ESPR were $307.56M, while the Total Assets stand at $314.11M.

As of the last quarter, how much Total Debt did Esperion Therapeutics, Inc. have?

The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of ESPR's debt was $268.96M at the end of the last quarter.

What were ESPR's Total Liabilities during the last reported quarter?

A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, ESPR reported total liabilities of $684.32M.

How much did ESPR's Working Capital change over the last quarter?

Working Capital Change for ESPR was $26.80M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.

ESPR generated how much cash from operating activities?

An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. ESPR generated -$35.33M of Cash from Operating Activities during its recently reported quarter.

What was ESPR's latest reported Net Change in Cash?

An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. ESPR reported a -$44.59M Net Change in Cash in the most recent quarter.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph